Luke (on behalf of Brian Skorney)'s questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q3 2024
Question
Luke, on behalf of Brian Skorney, asked about Xenon's strategy for developing azetukalner in pediatric patients with focal onset seizures (FOS) and whether these efforts could begin before the X-TOLE2 data readout.
Answer
CEO Ian Mortimer confirmed that Xenon has agreed-upon pediatric plans with both the FDA and EMA, and these plans are not contingent on the X-TOLE2 data. He mentioned that work on a pediatric formulation and juvenile toxicology studies is already proceeding in parallel. CMO Dr. Christopher Kenney added that dose adjustments for weight will be a key consideration for these younger patient populations.